Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells.

Zitzmann K, Ailer G, Vlotides G, Spoettl G, Maurer J, Göke B, Beuschlein F, Auernhammer CJ.

Int J Oncol. 2013 Dec;43(6):1824-32. doi: 10.3892/ijo.2013.2130.

2.

Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.

Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T; Australian Prostate Cancer BioResource., Tilley WD, Butler LM.

Clin Cancer Res. 2012 Jul 1;18(13):3562-70. doi: 10.1158/1078-0432.CCR-12-0782.

3.

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.

Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia-Echeverria C, Chène P.

Breast Cancer Res. 2008;10(2):R33. doi: 10.1186/bcr1996.

4.

Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.

Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh E, Schrader M, Ocker M, Scherübl H, Höpfner M.

Int J Oncol. 2012 May;40(5):1659-67. doi: 10.3892/ijo.2012.1328.

PMID:
22246317
5.

Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.

Steinmann S, Gali-Muhtasib H, Huebner K, Al-Halabi R, Abou Merhi R, Aman P, Agaimy A, Haller F, Schneider-Stock R.

Cancer Lett. 2015 Oct 28;367(2):147-56. doi: 10.1016/j.canlet.2015.07.025.

PMID:
26225840
6.

Anticancer effects of metformin on neuroendocrine tumor cells in vitro.

Vlotides G, Tanyeri A, Spampatti M, Zitzmann K, Chourdakis M, Spttl C, Maurer J, Nölting S, Göke B, Auernhammer CJ.

Hormones (Athens). 2014 Oct-Dec;13(4):498-508. doi: 10.14310/horm.2002.1517.

7.

The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.

Park KS, Oh B, Lee MH, Nam KY, Jin HR, Yang H, Choi J, Kim SW, Lee DH.

Cancer Lett. 2016 Mar 1;372(1):75-81. doi: 10.1016/j.canlet.2015.12.015.

PMID:
26723875
8.

Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.

Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ.

J Clin Endocrinol Metab. 2015 Feb;100(2):E253-61. doi: 10.1210/jc.2014-3101.

PMID:
25389633
9.

Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.

Djuzenova CS, Blassl C, Roloff K, Kuger S, Katzer A, Niewidok N, Günther N, Polat B, Sukhorukov VL, Flentje M.

Cancer Biol Ther. 2012 Apr;13(6):425-34. doi: 10.4161/cbt.19294.

PMID:
22286776
10.

Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.

Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, Slamon DJ, Finn RS.

Mol Cancer Ther. 2013 Apr;12(4):509-19. doi: 10.1158/1535-7163.MCT-12-0507.

12.

Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.

Bao XH, Takaoka M, Hao HF, Fukazawa T, Yamatsuji T, Sakurama K, Takigawa N, Nakajima M, Fujiwara T, Naomoto Y.

Oncol Rep. 2013 Jan;29(1):45-50. doi: 10.3892/or.2012.2074.

PMID:
23064324
13.

The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.

Walsby EJ, Lazenby M, Pepper CJ, Knapper S, Burnett AK.

Br J Haematol. 2013 Apr;161(1):57-67. doi: 10.1111/bjh.12215.

PMID:
23356405
14.

Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.

Spampatti M, Vlotides G, Spöttl G, Maurer J, Göke B, Auernhammer CJ.

World J Gastroenterol. 2014 Aug 7;20(29):10038-49. doi: 10.3748/wjg.v20.i29.10038.

15.

Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins.

Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.

Cancer Sci. 2011 Jul;102(7):1388-95. doi: 10.1111/j.1349-7006.2011.01944.x.

16.

HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.

Chen SM, Guo CL, Shi JJ, Xu YC, Chen Y, Shen YY, Su Y, Ding J, Meng LH.

Int J Cancer. 2014 Nov 15;135(10):2462-74. doi: 10.1002/ijc.28880.

17.

Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.

Wu X, Marmarelis ME, Hodi FS.

PLoS One. 2013;8(2):e56134. doi: 10.1371/journal.pone.0056134.

18.

Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.

Monazzam A, Razifar P, Ide S, Rugaard Jensen M, Josephsson R, Blomqvist C, Langström B, Bergström M.

Nucl Med Biol. 2009 Apr;36(3):335-42. doi: 10.1016/j.nucmedbio.2008.12.009.

PMID:
19324279
19.

Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.

Ueno T, Tsukuda K, Toyooka S, Ando M, Takaoka M, Soh J, Asano H, Maki Y, Muraoka T, Tanaka N, Shien K, Furukawa M, Yamatsuji T, Kiura K, Naomoto Y, Miyoshi S.

Lung Cancer. 2012 Apr;76(1):26-31. doi: 10.1016/j.lungcan.2011.09.011.

PMID:
21996088
20.

Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.

Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Y, Gajula RP, Williams RD, Cades JA, Annadanam A, Song D, Zhang Y, Hales RK, Herman JM, Armour E, DeWeese TL, Schaeffer EM, Tran PT.

Cancer Biol Ther. 2013 Apr;14(4):347-56. doi: 10.4161/cbt.23626.

Items per page

Supplemental Content

Support Center